LifeMD (LFMD) Earnings Date & Reports

Key Takeaways

• LifeMD (LFMD) is scheduled to report third-quarter 2026 results on November 12, 2026, after rescheduling from its original November 9 date.
• Wall Street consensus calls for a loss of about $0.14 per share on revenue of roughly $48.8 million, implying a nearly 19% year-over-year revenue decline.
• The company missed both top- and bottom-line estimates in Q2 2026 and lowered its full-year 2026 revenue outlook.
• GLP-1 (glucagon-like peptide-1) weight-management demand remains the biggest growth lever — and the biggest source of competitive pressure.
• Subscriber counts, gross margin, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) will be closely watched.
• Analysts still rate LFMD a Buy or Strong Buy, with an average price target near $8.13.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated LFMD pages on Tickeron.
• Explore Trending AI Robots to see AI-driven trading strategies in action.

Earnings Context and Why It Matters

LifeMD is a direct-to-patient telehealth and pharmacy company, operating brands including LifeMD, RexMD, and ShapiroMD. Its third-quarter report lands at a pivotal moment: the company is transitioning its weight-management business from compounded therapies toward branded GLP-1 (glucagon-like peptide-1) treatments amid intense, low-cost competition. After missing expectations in Q2 2026 and trimming its full-year revenue guidance, investors will look for signs that subscriber momentum and gross margins are stabilizing. With the stock trading near the low end of its 52-week range, this print will test whether management's growth narrative and path back to adjusted EBITDA profitability remain intact.

Earnings Expectations

For the third quarter ended September 30, 2026, analysts expect LifeMD to report a loss of approximately $0.14 per share, wider than the $0.10 loss recorded a year earlier. Consensus revenue is pegged near $48.8 million, a decline of roughly 19% from the $60.2 million reported in Q3 2025, reflecting the divestiture of WorkSimpli and softer weight-management dynamics.

Investors will focus on active subscriber growth, gross margin, and adjusted EBITDA, a non-GAAP (non-Generally Accepted Accounting Principles) profitability measure. In Q2 2026, revenue of $47.28 million missed the roughly $49.1 million estimate, and the company lowered its full-year 2026 revenue guidance to between $205.5 million and $212.5 million. Whether management reaffirms or adjusts that outlook will be a central question on the call.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your own watchlist ahead of this earnings event.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious. LFMD shares have fallen sharply over the past year and closed near $2.10 in the days before the release, near the low end of a 52-week range of roughly $1.88 to $5.44. Following Q2 2026 results, the stock declined on a top- and bottom-line miss combined with reduced guidance. Elevated short interest, representing a meaningful portion of the float, adds to the potential for volatility around the print. A revenue or subscriber surprise in either direction could drive outsized moves given the stock's history of sharp post-earnings swings.

Forward Outlook and Key Factors to Monitor

The most important forward-looking signal will be guidance. After lowering the 2026 revenue outlook in August, management's commentary on the fourth quarter and any early read on 2027 will shape the market's interpretation. Investors should listen for whether the transition from compounded to branded GLP-1 therapies is stabilizing revenue, and whether recently launched offerings in women's and men's health are scaling quickly enough to offset weight-management softness.

Cost trends also matter. LifeMD has been spending heavily on patient acquisition, and the pace of selling and marketing expense relative to revenue will indicate whether margin recovery is on track. Management has previously targeted a return to adjusted EBITDA profitability later in 2026, so any update on that timeline is a key catalyst.

Finally, watch balance-sheet and liquidity commentary. The company ended Q2 2026 with a modest cash position and no material debt, and it disclosed covenant-compliance and internal-control remediation items earlier in the year. Progress on those fronts, alongside subscriber retention metrics, will help investors gauge execution risk in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations